Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Life Science Investing
NRx Pharmaceuticals Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System Life Science Investing
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults Life Science Investing
PVG Asset Management to Host Investor Call Regarding Anavex Life Sciences Proxy Campaign Life Science Investing
Incyte Announces Funding of MINJUVI® for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program Life Science Investing
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors Life Science Investing
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting Life Science Investing
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium Life Science Investing
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader Life Science Investing
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference Life Science Investing
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026Â
